USP <788> Particulate Matter in Injections is the U.S. Pharmacopeia general chapter that sets the limits for subvisible particulate matter in injectable preparations and defines the test methods. For anyone working in QC and QA of sterile products, it is one of the most scrutinized compendial references during inspections: it states how many particles ≥10 µm and ≥25 µm are allowed per container or per milliliter, which method to run first, and what to do when the sample is not suitable for optical counting. This guide covers what USP <788> requires, the exact limits for SVP and LVP, how it relates to the other pharmacopeias, and the mistakes that most often trigger findings.
What is USP <788> Particulate Matter in Injections
USP <788> is a general chapter numbered below <1000>: it is therefore an enforceable test method, not merely informational guidance. It governs subvisible particulate matter, i.e. the extraneous, mobile, undissolved particles (other than gas bubbles) that may be present in injectable solutions and infusions. It should not be confused with visible particulate matter, which is covered by USP <790> and 100% container inspection.
The chapter is harmonized within the Pharmacopoeial Discussion Group (PDG) with Ph. Eur. 2.9.19 and the Japanese Pharmacopoeia (JP): methods, size categories and limits are aligned, allowing manufacturers serving multiple markets to maintain a single set of specifications. Together with sterility and endotoxins, particulate control is one of the critical quality attributes of every parenteral product, because excessive particles can have direct clinical consequences (phlebitic reactions, embolization, immune activation).
Method 1 (Light Obscuration) and Method 2 (Microscopic)
USP <788> provides two methods. Method 1 – Light Obscuration Particle Count is the method of choice and must be applied first: a sensor detects the light reduction caused by each particle passing through and converts it into a size distribution. It is fast, automatable and suitable for most clear solutions.
Method 2 – Microscopic Particle Count is used when Method 1 is not applicable — for example with products of reduced clarity or high viscosity, emulsions, colloids, liposomal preparations, or solutions that generate gas or air bubbles — or as a confirmatory method. Particles are collected on a membrane and counted under the microscope: it is more labor-intensive and subject to operator subjectivity, but remains essential for matrices unsuitable for optical reading. Note: the two methods have different acceptance limits and are not automatically interchangeable. For sampling, containers with a nominal volume above 25 mL are tested individually, whereas for smaller volumes several units (typically 10 or more) are combined to reach the required test volume.
Particulate control is one of many points where a compendial detail makes the difference between a released batch and a finding. Practical, audit-ready insights like this arrive every week with The Pragmatic GMP, our free newsletter for GxP professionals: subscribe so you don't miss the next ones.
USP <788> acceptance limits: SVP and LVP
The limits depend on the method used and the nominal container volume. Small-volume parenterals (SVP, ≤ 100 mL) are assessed per container, large-volume parenterals (LVP, > 100 mL) per milliliter. The table summarizes the limits set by USP <788>.
| Category | Method 1 – Light Obscuration | Method 2 – Microscopic |
|---|---|---|
| SVP ≤ 100 mL (per container) | ≤ 6000 particles ≥ 10 µm ≤ 600 particles ≥ 25 µm |
≤ 3000 particles ≥ 10 µm ≤ 300 particles ≥ 25 µm |
| LVP > 100 mL (per mL) | ≤ 25 particles/mL ≥ 10 µm ≤ 3 particles/mL ≥ 25 µm |
≤ 12 particles/mL ≥ 10 µm ≤ 2 particles/mL ≥ 25 µm |
A frequent mistake is comparing light-obscuration results against the microscopic limits (or vice versa): Method 2 limits are stricter and must always be read together with the method actually used.
USP <788>, <787>, <789> and <790>: which chapter applies
USP <788> is the general reference for injectables, but it is not the only chapter on particulate matter. To choose the right one, start from the nature of the product.
- USP <788> — subvisible particulate matter in conventional injections and infusions (most parenterals).
- USP <787> — subvisible particulate matter in therapeutic protein injections/biologics, with reduced sample volumes and attention to proteinaceous particles, while keeping the ≥ 10 µm and ≥ 25 µm thresholds.
- USP <789> — particulate matter in ophthalmic solutions, with limits dedicated to this route of administration.
- USP <790> — visible particulates in injections: requires products essentially free of visible particles and 100% inspection of units.
Detailed methodological and instrumental aspects (system suitability, alternative techniques) are instead addressed in the informational chapter USP <1788>.
Common mistakes found in audits
- Wrong method for the matrix: applying Light Obscuration to emulsions, colloids or viscous solutions without demonstrating suitability, when Method 2 would be required.
- Confusing the two methods' limits: evaluating optical-count results against microscopic limits, or failing to state in the report which method was used.
- Wrong volume category: applying the LVP "per mL" limits to an SVP (or vice versa), using the wrong calculation basis.
- Uncontrolled sample preparation: non-standardized shaking, degassing and glassware rinsing, leading to "environmental" particulate contamination and false exceedances.
- Instrument suitability not demonstrated: particle counter not qualified or lacking periodic verification with size and count standards.
- No link to the CCS: out-of-trend particulate results that do not feed the investigation or the site's Contamination Control Strategy.
GuideGxP recommendation
Treat USP <788> as part of the system, not as an isolated test. Define an SOP that, for each product, states the applicable chapter (<788>, <787>, <789>), the method of choice and the documented rationale for any switch to Method 2, the volume category and the corresponding limits. Standardize sample preparation (low-particulate environment, rinsing, degassing) and qualify the counter with periodic checks of size accuracy and count. Finally, link particulate trends to OOS/OOT investigation and to the Contamination Control Strategy: in an inspection the question won't only be "is the batch within limits?", but "how do you govern and monitor this attribute over time?".
To manage USP and Ph. Eur. compendial choices consistently and defend them in audits, take a look at our guide Pharmacopeias and GMP Audits: operational management of USP, Ph. Eur. and multi-region compliance: audit-ready frameworks and best practices for the QC lab.
